Ranbaxy Recalls Generic Lipitor In US For Possible Presence Of Glass Particle

  • Rate this Story
  • 0
  • 0

By Sreeja V N | November 23, 2012 10:02 PM EST

Ranbaxy Laboratories Ltd, India’s largest drug manufacturer by sales, has announced a voluntary recall of its cholesterol-lowering generic drug -- Lipitor -- from the U.S. market.

Ranbaxy’s U.S. wing, Ranbaxy Pharmaceuticals Inc, has recalled various batches of the Atorvastatin calcium tablets -- a generic version of the Lipitor drug -- from the market, the company has said in a statement.

“Ranbaxy Pharmaceuticals Inc. is conducting a voluntary recall for Atorvastatin calcium tablets, in connection with its 10mg 20mg and 40mg dosage strengths, packaged in 90’s and 500 count bottles and only with respect to certain select lot numbers. The recall does not affect or relate to the 80mg strength,” according to a statement on the company’s website.

Ranbaxy was the first company to launch the generic version of the Lipitor after Pfizer Inc's patent expired in November, 2011. The drug was responsible for generating $600 million in sales for the company.

Ranbaxy had compliance issues with the U.S. Food and Drug Administration (FDA) in the past. The FDA banned shipments from some of Ranbaxy’s manufacturing units in 2009 following which the company agreed to take corrective steps in its plants, Reuters reported.

However, industry experts have said that the current recall indicates that such corrective measures are not adequate and the recall will affect the company’s revenues.

"The development will impact the company's credibility to an extent," said Bhagwan Singh Chaudhary, a research associate at the brokerage IndiaNivesh

"There have been issues in the past (about compliance) and a recall suggests, corrective measures suggested by the US FDA are not being implemented," he added, according to Reuters.

However, Ranbaxy said that the recall was being done keeping customers’ safety in mind and the FDA had full knowledge of the issue.

“The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles approximately less than 1mm in size). Ranbaxy is proactively recalling the drug product lots out of an abundance of caution, and in keeping the safety of our customers in mind. This recall is being conducted with the full knowledge of the U.S. FDA,” the company said.

Click here for the complete list of the batches of drug being recalled.

To contact the editor, e-mail:

  • Rate this Story
  • 0
  • 0
This article is copyrighted by International Business Times, the business news leader

Join the Conversation

IBTimes TV
E-Newsletters

We value your privacy. Your email address will not be shared.